miophthalmology products

Optos’ Silverstone RGB can play a valuable role in the early detection and ongoing management of myopia by providing clinicians with an unparalleled view of the retina.

As the only ultra-widefield retinal imaging device capable of capturing 200° – or up to 82% of the retina – in a single image, Silverstone RGB enables visualisation of peripheral retinal changes that may be associated with myopic eye growth and progression. Combined with integrated swept-source optical coherence tomography, clinicians can assess retinal structure from the posterior pole to the far periphery, helping identify pathology earlier, monitor disease progression more effectively, and support informed treatment decisions for patients at risk of developing high myopia and its associated complications.

Contact: Optos auinfo@optos.com or visit optos.com

Myopia Forecast – an option for Optopol’s Revo optical coherence tomography devices – integrates biometry and corneal topography of both front and back surfaces with lineage and environmental factors to deliver a complete clinical picture.

The software automatically calculates axial length growth rate and compares it visually against Asian, European, or Tideman normative databases. Colour coded parameters and clear charts help practitioners track treatment response, communicate outcomes to patients and carers, and reinforce adherence.

Quantitative analysis enables rapid evaluation of treatment efficacy so clinicians can validate success or adjust recommendations with confidence. Myopia Forecast streamlines workflow, supports informed conversations, and strengthens patient and family engagement in myopia management.

Visit: optopol.au

OphthalmoPro’s Eyefos advanced optical coherence tomography (OCT) system is an artificial intelligence (AI)-enabled spectral-domain OCT platform with integrated ocular biometry designed to support precision ophthalmic assessment, with particular relevance to myopia management.

The system acquires high-resolution retinal and optic nerve head volumetric scans alongside biometric parameters including axial length, anterior chamber depth, lens thickness, keratometry, white-to-white, and central corneal thickness within a single workflow. Automated segmentation and AI-assisted analysis facilitate objective structural evaluation and longitudinal monitoring. The integration of anatomical imaging and biometric progression data enables improved risk stratification and evidence-based monitoring of axial elongation in paediatric and progressive myopia management pathways.

Contact: Ophthalmopro (AUS) 1300 578 288 or (NZ) 0800 578 288

Oertli’s surgical platforms are designed to support ophthalmic surgeons, particularly vitreoretinal specialists, by enhancing their surgical experience. The OS 4 system offers a versatile solution for posterior segment surgery, featuring a multi-pump fluidics system with proprietary SPEEP (speed and precision) function and optional integrated laser and illumination options.

Its design supports efficient workflow and precise control during delicate procedures. To expand on these possibilities, the Faros system balances portability with advanced dual-pump functionality at a low cost. The CataRhex 3 provides a compact alternative for cataracts, for mobile or space-limited environments.

Contact: eyes@device.com.au

The Eyerising Myopia Management Device (EMMD) is a non-invasive, home-use technology designed to slow myopia progression through repeated low-level red-light (RLRL) therapy. The treatment protocol consists of two three-minute sessions per day, five days per week. Supported by more than 40 peer-reviewed publications including randomised control trials and real-world studies,* EMMD has received regulatory approvals in Australia (ARTG ID: 412752), New Zealand, Europe, and other markets. Clinical studies have reported significant reductions in axial elongation, with one study reporting axial shortening in 53.3% of participants with high myopia.1 Available through more than 100 clinics across Australia and New Zealand, EMMD provides eye care professionals with an additional evidence-based option for myopia management.

Contact: Eyerising International (AUS) 1800 039 374 or eyerisinginternational.com